Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (June 7th Preview)
-
Obesity pharmacology: new retatrutide safety/tolerability updates
Eli Lilly disclosed additional safety and tolerability data for retatrutide at the American Diabetes Association meeting and in The Lancet, extending results from TRANSCEND-T2D-1. The company reported that among 403 participants receiving retatrutide, 7 experienced arrhythmias and 3 had major cardiovascular complications, compared with none in the placebo group. The update keeps attention on retatrutide’s near-term risk–benefit profile as obesity drug developers race to define long-term cardiovascular safety and differentiate efficacy in people with and without type 2 diabetes. Lilly has previously highlighted rapid weight loss with the next-generation, multi-receptor approach.
-
Monthly GLP-1/analogs: Pfizer’s berobenatide data reinforce dosing cadence
Pfizer reinforced its obesity and diabetes case for berobenatide with new mid-stage results presented at ADA and reported by STAT+. In the VESPER-3 study, patients transitioned from weekly dosing to higher monthly doses, with weight loss continuing through 28 weeks and no plateau yet. Separately, another ADA session-focused report says Pfizer is also “padding the case” for berobenatide in obesity, adding validation for the Metsera acquisition. The company continues to position monthly administration as a practical option versus weekly injectables already competing in the obesity market.
-
Ebola diagnostics: WHO scales point-of-care molecular testing plan
The World Health Organization unveiled a six-month plan to stamp out the current Bundibugyo Ebola virus outbreak in Africa, including a major scale-up of point-of-care molecular diagnostics. WHO said it will expand a KH Medical point-of-care PCR system while strengthening reference laboratory capacity for testing and sequencing-based surveillance. WHO director-general Tedros Adhanom Ghebreyesus said the effort requires about $518 million. Africa CDC director-general Jean Kaseya noted the outbreak has already surpassed earlier Bundibugyo case counts at comparable timepoints and emphasized that delays in diagnostics can amplify case-fatality.
-
Clinical pipeline: Roche moves to Phase 2 on obesity combo petrelintide and enicepatide
Roche said it will start a Phase 2 trial combining petrelintide and enicepatide this year, targeting obesity with an eye toward differentiating safety and efficacy across its amylin-based program. The company framed the pairing as a potential best-in-class opportunity if the two incretin and amylin-pathway mechanisms act synergistically. The announcement came around ADA 2026 coverage, underscoring how Roche is advancing next-stage development decisions for obesity assets with ongoing competition in GLP-1-based regimens.
-
ADC momentum: first-in-human antibody–drug conjugate readouts at ASCO
Antibody–drug conjugates headlined first-in-human development at ASCO, according to BioCentury’s analysis of 137 FIH studies highlighted at the meeting. The review found that ADCs accounted for about 20% of first-in-human trials, with a continued diversity of payloads, designs, and targets. The report also highlighted how China featured prominently for both translational programs and early-stage clinical research, while U.S. biopharmas maintained an edge in first-in-class clinical development. The takeaway for sponsors is continued investment in ADC platforms despite evolving payload and linker safety profiles.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.